-
ECHR condemns Italy's response to toxic waste crisis Lancet Oncol. (IF 41.6) Pub Date : 2025-02-07 Talha Burki
No Abstract
-
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-07 Diana Romero
Patients with HER2-negative advanced-stage gastric or gastro-oesophageal junction (G/GEJ) adenocarcinomas typically receive chemotherapy with or without an anti-PD-1 antibody as first-line treatment. Now, data from the phase III COMPASSION-15 trial show that combination of the PD-1 × CTLA4 bispecific antibody cadonilimab plus chemotherapy is also efficacious in this setting. In this trial, conduced
-
Dendritic cell maturation in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2025-02-07 Chang Yoon Moon, Meriem Belabed, Matthew D. Park, Raphaël Mattiuz, Daniel Puleston, Miriam Merad
-
Law to extend free medical treatment for breast cancer in France Lancet Oncol. (IF 41.6) Pub Date : 2025-02-06 Barbara Casassus
No Abstract
-
More than three in five kidney cancer diagnoses in the UK are incidental Lancet Oncol. (IF 41.6) Pub Date : 2025-02-06 Elizabeth Gourd
No Abstract
-
Transanal TME noninferior to the laparoscopic approach Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-06 Peter Sidaway
Patients with resectable mid–low rectal cancers often undergo total mesorectal excision (TME) surgery. Over the past decade, considerable research interest has been focused on minimally invasive TME procedures that might offer improved perioperative outcomes and preservation of sphincter function, including laparoscopic and transanal approaches. Despite some evidence of an increased risk of local recurrence
-
International approvals of cilta-cel: a lens on CAR T cell regulation Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-06 Chenghao Ge, Chen Yin, Xiaoyuan Chen
The BCMA-targeted chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel (cilta-cel) has demonstrated exceptional efficacy in studies conducted worldwide, which has resulted in regulatory approvals in >40 countries. Herein, we examine the regulatory pathways that led to its approval in different regions, focus on challenges in clinical development and regulatory submission, and provide
-
LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 Eunae You, Bidish K. Patel, Alexandra S. Rojas, Siyu Sun, Patrick Danaher, Natalie I. Ho, Ildiko E. Phillips, Michael J. Raabe, Yuhui Song, Katherine H. Xu, Joshua R. Kocher, Peter M. Richieri, Phoebe Shin, Martin S. Taylor, Linda T. Nieman, Benjamin D. Greenbaum, David T. Ting
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that require mechanisms to manage this repeat “viral” load and attenuate innate immune responses. Here, we show that the LINE-1 ORF1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor (PRR)-mediated antiviral response that is independent of retrotransposition
-
Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research. Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 Lawrence W Wu,Ryan H Moy,
Individuals in the United States from Asian and Asian American, Native Hawaiian, and Pacific Islander (AANHPI) backgrounds face a distinct set of cancer-related disparities. In this study, in conjunction with the American Association for Cancer Research Asian/AANHPI Task Force, we highlight the unique disparities faced by AANHPI patients and professionals, and we offer actionable recommendations on
-
Knudson’s “Two-Hit” Hypothesis and Cancer Predisposition: A Bit More Complicated but Still Going Strong Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 Jack J. Brzezinski, David Malkin
Summary: This study by Treger and colleagues is a comprehensive evaluation of the genome and epigenome of tumors and constitutional tissue from children with Wilms tumor predisposition syndromes that demonstrates that the molecular features of Wilms tumors are dependent on the constitutional milieu of the patient in which they develop. See related article by Treger et al., p. 286
-
A Material Transfer Agreement between Glioblastoma and Normal Brain Cells Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 Sajina Shakya, Christopher G. Hubert, Justin D. Lathia
Summary: Tumor cells communicate with normal cells in various ways, typically leading to the exploitation of resources of the normal cells by tumor cells for their benefit. In this issue, Mangena and colleagues use three-dimensional organoid models to show the transfer of GFP and mRNA from malignant glioblastoma to nonmalignant cells in cerebral organoid models; this transfer is facilitated by extracellular
-
Hidden in Plain Sight: Clinical Imaging of the Tumor Microenvironment with PET Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 Timothy H. Witney
Summary: PET imaging enables the spatiotemporal assessment of tumor biomarkers. In this issue, Kong and colleagues describe the clinical PET imaging of tumor-associated fibroblasts, which improved the diagnostic accuracy and management of a subset of patients with medullary thyroid carcinoma. See related article by Kong et al., p. 316
-
Stromal KITL/SCF maintains pancreas tissue homeostasis and restrains tumor progression Cancer Discov. (IF 29.7) Pub Date : 2025-02-07 M. Kathrina. Oñate, Chet Oon, Sohinee Bhattacharyya, Vivien Low, Canping Chen, Xiaofan Zhao, Frank Arnold, Ziqiao Yan, Sneha Pramod, Yan Hang, Yu-Jui Ho, Scott W. Lowe, Seung K. Kim, Zheng Xia, Mara H. Sherman
Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to immune and non-immune stromal elements enable loss of homeostasis during tumor onset. The precise mechanisms by which normal stromal cell states limit tissue plasticity and tumorigenesis, and which are lost during
-
Anlotinib versus placebo as adjuvant therapy for localized high-grade soft tissue sarcomas: a phase 2, double-blinded, randomized controlled trial Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-07 Chunmeng Wang, Xianglin Hu, Lingge Yang, Yu Xu, Biqiang Zheng, Jilong Yang, Zhichao Liao, Zhengwang Sun, Shengjian Zhang, Lin Yu, Yan Yan, Yong Chen, Tomohiro Fujiwara, Jianrong Zhang, Ilia N. Buhtoiarov, Yangbai Sun, Wangjun Yan
Purpose: We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft tissue sarcomas (STS). Patients and Methods: Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1-14 every 21 days as a cycle, with
-
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance Cancer Cell (IF 48.8) Pub Date : 2025-02-06 Felicity Newell, Ines Pires da Silva, Peter A. Johansson, Alexander M. Menzies, James S. Wilmott, Venkateswar Addala, Matteo S. Carlino, Helen Rizos, Katia Nones, Jarem J. Edwards, Vanessa Lakis, Stephen H. Kazakoff, Pamela Mukhopadhyay, Peter M. Ferguson, Conrad Leonard, Lambros T. Koufariotis, Scott Wood, Christian U. Blank, John F. Thompson, Andrew J. Spillane, Georgina V. Long
(Cancer Cell 40, 88–102; January 10, 2022)
-
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer Cancer Cell (IF 48.8) Pub Date : 2025-02-06 Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Ning Zhao, Xiaoying Sun, Baolin Liu, Ranran Gao, Binghe Xu, Zemin Zhang, Zhihua Liu, Fei Ma
-
Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases Cancer Cell (IF 48.8) Pub Date : 2025-02-06 Francisco Javier Rodriguez-Baena, Angel Marquez-Galera, Pablo Ballesteros-Martinez, Alba Castillo, Eva Diaz, Gema Moreno-Bueno, Jose P. Lopez-Atalaya, Berta Sanchez-Laorden
-
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis Lancet Oncol. (IF 41.6) Pub Date : 2025-02-05 Ryan S Huang, Ronald Chow, Ali Benour, David Chen, Gabriel Boldt, Christopher J D Wallis, Anand Swaminath, Charles B Simone, Michael Lock, Srinivas Raman
BackgroundNon-invasive and minimally invasive ablative treatments, including stereotactic body radiotherapy (SBRT), radiofrequency ablation, microwave ablation, and cryoablation, have emerged as key treatment options for managing renal cell carcinoma, especially for patients who are unsuitable for surgery. We aimed to compare the clinical efficacy and safety of these emerging treatment methods in patients
-
Hijacking of the nervous system in cancer: mechanism and therapeutic targets Mol. Cancer (IF 27.7) Pub Date : 2025-02-06 Yu Zhang, Qili Liao, Xuyang Wen, Jiayan Fan, Tifei Yuan, Xuemei Tong, Renbing Jia, Peiwei Chai, Xianqun Fan
The activity of neurons in the vicinity of tumors is linked to a spectrum of cellular mechanisms, including the facilitation of tumor cell proliferation, synapse formation, angiogenesis, and macrophage polarization. This review consolidates the current understanding of neuro-oncological regulation, underscoring the nuanced interplay between neurological and oncological processes (termed as Cancer-Neuroscience)
-
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes Cancer Discov. (IF 29.7) Pub Date : 2025-02-06 Marina N. Sharifi, Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, Viridiana Carreno, Katherine R. Kaufmann, Alex H. Chang, Luke A. Nunamaker, Charlotte Linebarger, Leilani Mora-Rodriguez, Jennifer L. Schehr, Hannah M. Krause, Kyle T. Helzer, Matthew L. Bootsma, Grace C. Blitzer, John M. Floberg, Christos E. Kyriakopoulos, Hamid Emamekhoo, Elisabeth I. Heath, Meghan Wells,
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance has been limited by the challenges of collecting serial tissue biopsies on treatment, which can be overcome using blood-based liquid biopsies. Utilizing a novel circulating
-
A Call for Improved Guidance to Integrate Modern Biomarkers Into Routine Clinical Care-Piecing the Puzzle Together. JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Catherine Dunn,Jeanne Tie,Peter Gibbs
-
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsell, Rowan E. Miller
ImportanceAdvanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported in CCGC merits further investigation.ObjectiveTo assess the clinical benefit of pembrolizumab in patients with previously treated advanced CCGC.Design, Setting, and
-
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Mark Roschewski, Dan L. Longo, James O. Armitage
ImportanceAchieving remission is the first step toward a cure in treating aggressive B-cell lymphomas. Radiographic imaging, such as fluorodeoxyglucose–positron emission tomography/computed tomography scans are the current standard to define remission at the end of therapy but lack specificity for lymphoma and cannot detect disease at the molecular level. Identifying measurable residual disease with
-
Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant-is it too soon to draw conclusions? J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-06 Meis Omran,David Malkin
-
A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-05 Shom Goel, Bojana Jovanović, Xiangying Chu, Melissa Hughes, Timothy K. Erick, Douglas Russo, Molly DiLullo, Eileen Wrabel, Rinath Jeselsohn, Nancy U. Lin, Nabihah Tayob, Elizabeth Mittendorf, Stuart Schnitt, Sara M. Tolaney
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in hormone receptor-positive metastatic breast cancer patients. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Methods: We conducted a single-arm phase II study of abemaciclib monotherapy
-
Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences after radiotherapy in SweBCG91-RT cohort Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-05 Rebecca J .G. Drake, Amalia H. Landén, Erik Holmberg, Axel Stenmark Tullberg, Fredrika Killander, Emma Niméus, Alexander Jordan, Jennifer McGuinness, Per Karlsson, Kairbaan Hodivala-Dilke
PURPOSE: Identifying biomarkers of radiotherapy (RT) response is important for optimising the treatment of early breast cancer (BC). Here we tested the interaction between endothelial cell (EC) expression of phospho-Tyr397-FAK (pY397-FAK) and adjuvant-RT on clinical outcomes after breast-conserving surgery (BCS) within a randomised study. Preclinical data suggests an enhanced effect of RT with low
-
UK's National Cancer Plan needs to be radical, accountable, and deliverable Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Mark Lawler, Pat Price
No Abstract
-
Fires and their smouldering health effects Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03
No Abstract
-
Mantle cell lymphoma: is it time for risk-adapted treatment? Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Ingrid Glimelius
No Abstract
-
Transforming oncology care in Latin America: artificial intelligence-driven solutions to bridge workforce gaps Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Fabio Y Moraes, Michael Yan, Ada Muellner, Hedvig Hricak
No Abstract
-
Thank you to The Lancet Oncology's reviewers in 2024 Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03
No Abstract
-
Aromatase inhibitors, cardiovascular medications, and patient outcomes Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Peng Luo, Jian Zhang, Anqi Lin
No Abstract
-
Aromatase inhibitors, cardiovascular medications, and patient outcomes – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye
No Abstract
-
CHIPOR: gaps in recurrent ovarian cancer management Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Atahan Toyran, Hamdullah Sozen, Yagmur Minareci, Samet Topuz, Yavuz Salihoglu
No Abstract
-
Correction to Lancet Oncol 2019; 20: 1750–59 Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03
Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750–59—In this Article, in the Outcomes section of the Methods, it was stated incorrectly
-
Correction to Lancet Oncol 2021; 22: 1081–92 Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021; 22: 1081–92—In this Article, in the
-
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer-Glusman, Jennifer Lin, James P Dean, Jutta K Neuenburg, Constantine S Tam
BackgroundThe combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety of ibrutinib–venetoclax compared with ibrutinib–placebo in patients with relapsed or refractory MCL. MethodsSYMPATICO is a multicentre, randomised, double-blind, placebo-controlled, phase
-
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Rebecca Kristeleit
BackgroundIn the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here, we present the final overall survival analysis of the trial and other post-progression outcomes. MethodsThis open-label, randomised, controlled phase
-
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Bishal Gyawali, Elizabeth A Eisenhauer, Winette van der Graaf, Christopher M Booth, Nathan I Cherny, Aaron M Goodman, Rachel Koven, Madeline L Pe, Bernard L Marini, Ghulam Rehman Mohyuddin, Gregory R Pond, Manju Sengar, Enrique Soto-Perez-de-Celis, Dario Trapani, Michelle Tregear, Brooke E Wilson, Ian F Tannock
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of randomised, controlled, phase 3 clinical trials evaluating cancer treatments. These principles include: (1) control treatment should be the best current standard of care; (2) the preferred primary endpoint
-
Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG) Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Colm Mac Eochagain, Nina Rosa Neuendorff, Karolina Gente, Jan Leipe, Marthe Verhaert, Christine Sam, Nienke de Glas, Sindhuja Kadambi, Beverly Canin, Fabio Gomes, Lore Decoster, Beatriz Korc-Grodzicki, Siri Rostoft, Nicolò Matteo Luca Battisti, Hans Wildiers
Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment landscape for a wide variety of malignancies. Older adults represent a large and rapidly growing demographic, among whom ICIs are widely prescribed. Management of ICI-associated toxicity among older adults, particularly in the presence of frailty and comorbidity, poses unique challenges. In this Policy Review, developed by
-
Differences in the on-label cancer indications of medicinal products between Europe and the USA Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Martina Perini, Beatrice Castiglioni, Elisabetta Galai, Dario Trapani, Armando A Genazzani, Gianluca Miglio
The definition of a therapeutic indication formulated by regulatory agencies is a decisive element for the marketing authorisation of medicinal products and for patient access. Trotta and colleagues found that oncological indications granted by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in the period between 1999 and 2008 were clinically different in about 10%
-
Rethinking metastatic brain cancer as a CNS disease Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Jawad Fares, Edgar Petrosyan, Crismita Dmello, Rimas V Lukas, Roger Stupp, Maciej S Lesniak
Advances in molecular biology, genetics, and epigenetics have refined our understanding of metastatic brain cancer and underscored the need for better classification and targeted approaches. The heterogeneity of brain metastases highlights the differences from their primary source of origin and contributes to therapeutic resistance. Before colonising the brain, tumour cells acquire specialised proficiencies
-
Bullous Wells syndrome in a patient with occult nasopharyngeal carcinoma Lancet Oncol. (IF 41.6) Pub Date : 2025-02-03 Mengmeng Li, Qingfeng Liu, Xiaomei Chen
Section snippets ContributorsAll authors cared for the patient. QL and ML wrote the initial draft. XC reviewed the manuscript. All authors read and approved the final version. Written informed consent to publication was obtained. Declaration of interestsWe declare no competing interests.
-
Multimodal lung cancer theranostics via manganese phosphate/quercetin particle Mol. Cancer (IF 27.7) Pub Date : 2025-02-04 Chong Qiu, Fei Xia, Qingchao Tu, Huan Tang, Yinan Liu, Hongda Liu, Chen Wang, HaiLu Yao, Linying Zhong, Yuanfeng Fu, Pengbo Guo, Weiqi Chen, Xinyu Zhou, Li Zou, Licheng Gan, Jiawei Yan, Yichong Hou, Junzhe Zhang, Huanhuan Pang, Yuqing Meng, Qiaoli Shi, Guang Han, Xijun Wang, Jigang Wang
The diagnosis and treatment of non-small cell lung cancer in clinical settings face serious challenges, particularly due to the lack of integration between the two processes, which limit real-time adjustments in treatment plans based on the patient’s condition and drive-up treatment costs. Here, we present a multifunctional pH-sensitive core-shell nanoparticle containing quercetin (QCT), termed AHA@MnP/QCT
-
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-03 Jia Luo, Justin A. Bishop, Steven G. DuBois, Glenn J. Hanna, Lynette M. Sholl, Edward B. Stelow, Lester D. R. Thompson, Geoffrey I. Shapiro, Christopher A. French
-
JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer Cancer Res. (IF 12.5) Pub Date : 2025-02-04 Chuanjie Zhang, Jiawei Ding, Kiat Shenq Lim, Wenjie Zhou, Wenyu Miao, Siqi Wu, Hanqing Liu, Da Huang, Chufeng Chen, Hongchao He, Jun Xiao, Dan-feng Xu, Yan Shen, Hai Huang, Yi Gao
Ferroptosis inducers have shown therapeutic potential in prostate cancer (PCa), but tumor heterogeneity poses a barrier to their efficacy. Distinguishing the regulators orchestrating metabolic crosstalk between cancer cells could shed light on therapeutic strategies to more robustly activate ferroptosis. Here, we found that aberrant accumulation of jumonji domain containing 6 (JMJD6) proteins correlated
-
Characterization of an Enhancer RNA Signature Reveals Treatment Strategies for Improving Immunotherapy Efficacy in Cancer Cancer Res. (IF 12.5) Pub Date : 2025-02-04 Chenyang Zhang, Yan-Yan Chen, Shuyu Chen, Yunzhe Wang, Yifan Yuan, Xiwen Yang, Wei Hu, Bo Chen, Zengxin Qi, Jason T. Huse, Yun Liu, Bo Wen, Xiuping Liu, Leng Han, Yuxiang Wang, Zhao Zhang
Non-coding RNA transcribed from active enhancers, known as enhancer RNA (eRNA), is a critical element in gene regulation with a highly specific expression pattern in the regulatory networks of tumor-infiltrating cells. Therefore, eRNA signatures could potentially be applied to represent anti-tumor immune cells and to improve cancer immunotherapy. Herein, we identified thousands of eRNAs that were significantly
-
Ribosomal RNA Biosynthesis Functionally Programs Tumor-Associated Macrophages to Support Breast Cancer Progression Cancer Res. (IF 12.5) Pub Date : 2025-02-04 Brandon J. Metge, Li'an Williams, Courtney A. Swain, Dominique C. Hinshaw, Amr R. Elhamamsy, Dongquan Chen, Rajeev S. Samant, Lalita A. Shevde
Macrophages are important cellular components of the innate immune system, serving as the first line of immune defense. They are also among the first immune cells to be reprogrammed by the evolving tumor milieu into tumor-supportive macrophages that facilitate tumor progression and promote therapeutic evasion. Here, we uncovered that macrophages from preneoplastic breast lesions were enriched for ribosome
-
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-04 Sara M. Tolaney, Thomas M. Cardillo, Chih-Chien Chou, Carrie Dornan, Mary Faris
Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is currently approved to treat metastatic triple-negative breast cancer and HR+/HER2– breast cancer, and is under clinical investigation for a range of other tumor types. This review describes its mode of action, development, and clinical outcomes. SG is composed of SN-38 (a topoisomerase I inhibitor derived from irinotecan) covalently
-
Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-04 Rebecca Landy, Gregory W Haber, Barry I Graubard, Carole Fakhry, Nicole G Campos, Emily A Burger, Li C Cheung, Hormuzd A Katki, Maura L Gillison, Anil K Chaturvedi
Background We estimated the impact of screening on morbidity and mortality of HPV16-positive oropharyngeal cancer among US men aged 45-79 years. Methods We developed an individual-level, state-transition natural history microsimulation model to estimate the impact of screening using oral HPV16 detection, HPV16-E6 antibody detection, and transcervical-ultrasound of neck/oropharynx. We compared clinical
-
Correction: The landscape of BRAF transcript and protein variants in human cancer Mol. Cancer (IF 27.7) Pub Date : 2025-02-03 Andrea Marranci, Zhijie Jiang, Marianna Vitiello, Elena Guzzolino, Laura Comelli, Samanta Sarti, Simone Lubrano, Cinzia Franchin, Ileabett Echevarría-Vargas, Andrea Tuccoli, Alberto Mercatanti, Monica Evangelista, Paolo Sportoletti, Giorgio Cozza, Ettore Luzi, Enrico Capobianco, Jessie Villanueva, Giorgio Arrigoni, Giovanni Signore, Silvia Rocchiccioli, Letizia Pitto, Nicholas Tsinoremas, Laura Poliseno
Correction: Mol Cancer 16, 85 (2017) https://doi.org/10.1186/s12943-017-0645-4 Following the publication of the original article [1], the authors would like to update Figure 8. They noticed that the graph in panel d was erroneously duplicated in panel h during the production process. The incorrect and correct figures are provided below. Incorrect Figure 8: Correct Figure 8: Marranci A, Jiang Z, Vitiello
-
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer Mol. Cancer (IF 27.7) Pub Date : 2025-02-03 Qingyu Huang, Wenhui Yang, Fuhao Wang, Rui Huang, Qian Wang, Xiaohui Li, Tianyu Lei, Shengqin Yue, Wenxue Zou, Qi An, Jinbo Yue, Qinyong Hu, Chao Liu
P-selectin (SELP) expression in tumor cells has been implicated in promoting tumor progression and treatment resistance across various cancers. However, our prior study identified SELP expression in a specific subpopulation of endothelial cells within cervical cancer (CC) and potentially linked to anti-cancer immune response. The precise mechanisms by which SELP influences anti-cancer immunity and
-
Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins Mol. Cancer (IF 27.7) Pub Date : 2025-02-03 Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle
Cancer creates an immunosuppressive environment that hampers immune responses, allowing tumors to grow and resist therapy. One way the immune system fights back is by inducing ferroptosis, a type of cell death, in tumor cells through CD8 + T cells. This involves lipid peroxidation and enzymes like lysophosphatidylcholine acyltransferase 3 (Lpcat3), which makes cells more prone to ferroptosis. However
-
Bcl-Xl Protects ASS1-Deficient Cancers From Arginine Starvation Induced Apoptosis Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-03 Prashanta Kumar. Panda, Ana Carolina. Paschoalini Mafra, Alliny C. S. Bastos, Li Cao, Maria Serra Bonet, Caitlyn B. Brashears, Ethan Yang. Chen, Heather M. Benedict-Hamilton, William Ehrhardt, John Bomalaski, Carina Dehner, Leonard C. Rogers, Toshinao Oyama, Brian A. Van Tine
Purpose: Argininosuccinate Synthetase 1 (ASS1) silencing in carcinomas and sarcomas leads to a dependence on extracellular arginine for survival. Arginine deprivation therapies, like PEGylated arginine deiminase (ADI-PEG20), have shown limited effectiveness, which may be due to underlying mechanisms that inhibit apoptosis. Experimental Design: The effects of ADI-PEG20 on cell cycle regulation, apoptosis
-
Mitochondria-targeting of oxidative phosphorylation inhibitors to alleviate hypoxia and enhance anticancer treatment efficacy Clin. Cancer Res. (IF 10.0) Pub Date : 2025-02-03 Anne P.M. Beerkens, Sandra Heskamp, Flavia V. Reinema, Gosse J. Adema, Paul N. Span, Johan Bussink
Hypoxia is a common feature of solid tumors and is associated with a poor response to anticancer therapies. Hypoxia also induces metabolic changes, such as a switch to glycolysis. This glycolytic switch causes acidification of the tumor microenvironment (TME), thereby attenuating the anticancer immune response. A promising therapeutic strategy to reduce hypoxia and thereby sensitize tumors to irradiation
-
Prognostic implications of risk definitions from the monarchE and NATALEE trials J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-03 Luca Arecco, Eva Blondeaux, Marco Bruzzone, Grazia Arpino, Carmine De Angelis, Michelino De Laurentiis, Roberta Caputo, Alessandra Fabi, Valeria Sanna, Stefania Gori, Fabio Puglisi, Luca Boni, Simone Nardin, Irene Giannubilo, Marta Perachino, Roberto Borea, Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini, Lucia Del Mastro
Background The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their inclusion criteria. Methods Patients with hormone receptor-positive/HER2-negative early breast cancer enrolled in the phase III MIG1, GIM2, and GIM3 trials were categorized as high-risk cohort (HRC) and low-risk cohort (LRC) according to the inclusion
-
Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-03 Qinjin Fan, Weichuan Dong, Elizabeth J Schafer, Nikita Sandeep Wagle, Jingxuan Zhao, Kewei Sylvia Shi, Xuesong Han, K Robin Yabroff, Leticia M Nogueira
The COVID-19 pandemic disrupted health care and reduced cancer diagnoses in the United States, raising concerns about its impact on time-to-treatment initiation (TTI), a critical factor for survival. This study examined the changes in TTI for 1 213 481 individuals newly diagnosed with female breast, nonsmall cell lung, colon, or rectal cancer between 2019 and 2022, using the National Cancer Database
-
Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-03 Sarah L Kerns, Paul C Dinh, Patrick O Monahan, Timothy Stump, Chunkit Fung, Howard D Sesso, Darren R Feldman, Robert J Hamilton, David J Vaughn, Robert Huddart, Christian Kollmannsberger, Neil E Martin, Kathryn Nevel, John Kincaid, Lawrence H Einhorn, Lois B Travis
Background To comprehensively evaluate the longitudinal progression of cumulative burden of morbidity (CBM) in testicular cancer survivors (TCS) following standard-dose cisplatin-chemotherapy and the impact of modifiable risk factors on morbidity and early-mortality. Methods Participants completed first-line chemotherapy ≥6 months before baseline assessments with comprehensive questionnaires and p
-
End-of-life care quality for American Indians with cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-03 Marc A Emerson, Lisa P Spees, Bradford E Jackson, Soroush Fariman, Joel Begay, Hayley N Morris, Ana I Salas, Christopher D Baggett, Tomi Akinyemiju, Ronny A Bell, Stephanie B Wheeler
Background American Indians (AI) experience disparities in cancer outcomes. Little is known about the quality of end-of-life (EOL) care in AI patients with cancer. Methods We retrospectively analyzed EOL care for North Carolina patients who died (decedents) diagnosed with any cancer (2003-2018) using the Cancer Information and Population Health Resource. Measures of EOL care quality were informed by
-
Using GPT-4o to interpret patient-reported outcomes without training. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-02-03 Thomas M Atkinson,Aleksandr Petrov,Kathleen A Lynch,Login S George,Jennifer R Cracchiolo,Bobby Daly,Kristen L Fessele,James H Flory,Jun J Mao,Yuelin Li